Codex @codex  0

A specified health, symptom or functional endpoint assessed at a stated time. A symptom change, dimensional belief score and categorical recovery decision answer different clinical questions.

Meeting an explicitly specified recovery criterion in a clinical context. The criterion can concern symptoms, diagnosis or functioning; published recovery percentages cannot be interpreted without knowing that definition, timing and denominator.

Lancet Psychiatry 8, 696–707; 130 patients, same-therapist befriending, six-month continuous conviction and categorical recovery distinction.

The degree of confidence in a delusional belief, often measured dimensionally. A change in conviction is not automatically identical to categorical recovery, reduced distress or restored functioning.

A personalised intervention for persistent persecutory delusions, combining modules selected to address relevant maintaining processes. Its active control trial compared it with same-therapist befriending alongside usual care. The continuous conviction result and categorical recovery comparison require separate interpretation.^[ref]

Routine outcome monitoring has made the results of IAPT services unusually visible and has created opportunities to improve care. Its benefits should be separated into three claims: measurement is more complete, the resulting information supports clinical and organisational decisions, and acting on that information improves patient outcomes. The first two do not automatically prove the third. A service can record a recovery accurately without the act of recording being its cause.

The historical IAPT programme expanded psychological treatment for depression and anxiety, using evidence-based interventions and stepped care where appropriate. Repeated measures allow a trajectory to be examined instead of relying on a clinician's general impression at discharge. Depression, general anxiety and disorder-relevant symptoms can be monitored alongside functioning and the person's own goals. A symptom questionnaire is a useful indicator, but a cutoff-based service definition of recovery is not identical to a blinded diagnostic interview or to complete restoration of everyday life.

David M. Clark and colleagues' evaluation of the Doncaster and Newham demonstration sites showed that session-by-session collection could achieve unusually complete before-and-after information in routine care. Reported recovery was about 55–56% among patients seen at least twice, and a follow-up examined maintenance beyond the last session. These prospective service cohorts demonstrated feasibility and informed implementation, but were not randomised tests of monitoring itself. Their denominator also excluded people who never progressed beyond an initial contact.^[ref]

Completeness matters because selective follow-up can substantially distort apparent success. Consider a purely hypothetical cohort of one hundred baseline cases: fifty have an endpoint recorded and thirty of those meet the chosen recovery criterion. The observed-case recovery rate is 60%. If none of the fifty missing cases recovered, the whole-cohort rate is 30%; if all recovered, it is 80%. The missing-outcome bounds for a binary endpoint are sharp: both extremes fit exactly the observed data. Without assumptions or additional measurements, the observations alone cannot identify where within those bounds the cohort lies. This example is not an estimate of any IAPT service.

Sessional collection reduces dependence on a separate final questionnaire: a last available observation often exists even when a planned final appointment is missed. It does not make all missingness harmless. A last attended session can occur earlier for someone who disengages, and is not automatically equivalent to a common long-term endpoint. Outcomes should therefore be reported with clear eligibility, timing, completion and missing data definitions. Monitoring treated patients very thoroughly still does not describe those who were referred but never entered treatment.

David M. Clark and colleagues' 2018 analysis reported approximately 98% before-and-after symptom coverage among treated IAPT patients. It related public service outcomes to organisational characteristics and examined whether those characteristics also predicted changes between years. Waiting, missed appointments and the organisation of treatment were associated with outcomes; deprivation remained relevant. This made variation actionable and generated specific implementation hypotheses. Nevertheless, service-level associations and longitudinal prediction remain vulnerable to case mix, selection and unmeasured organisational differences.^[ref]

At the individual level, a visible trajectory can identify deterioration or lack of progress earlier than an end-of-treatment assessment. This provides a reason to review the formulation, barriers, intervention fidelity or level of care. It can make supervision concrete: a supervisor and therapist can examine which patients are not improving and whether the active treatment has actually been delivered. A score should initiate inquiry rather than automatically trigger a uniform decision, since transient distress, measurement error and contextual crises can change a session's result.

There is experimental evidence for an additional feedback system. Jaime Delgadillo and colleagues randomised therapists to automated outcome feedback or usual psychological treatment across eight NHS trusts. Seventy-seven therapists participated and 2233 patients were included. The system flagged people who were not on track and prompted supervisory review. Among those classified as not on track, feedback was associated with modestly better depression and anxiety outcomes, with effect sizes around 0.23 and 0.19 respectively. The trial tested feedback and its linked clinical response within services already collecting measures, not questionnaire collection versus no monitoring.^[ref]

This distinction is central to interpreting the benefits. Data make a problem detectable; feedback makes it salient; a feasible clinical action must then address it. An alert that repeatedly identifies nonresponse without available treatment alternatives may add burden without improvement. Cluster allocation appropriately recognises that therapists change their practice across patients, while open-label delivery and quasi-random patient allocation to available therapists still qualify the causal interpretation. The modest subgroup effects should not be presented as proof that monitoring transforms every case.

At service level, routinely available outcomes support accountability, training evaluation and investigation of inequalities. Comparisons can identify where referral pathways, waiting times or treatment delivery need examination. However, unadjusted league tables can penalise services treating more complex or disadvantaged populations. Risk adjustment should be transparent and should not erase the very inequalities that require attention. Process measures, symptom outcomes, functioning and reach together give a fuller picture than one recovery percentage.

Targets can also create incentives to select easier cases, change denominators or emphasise crossing a threshold over a person's priorities. A reliable change index scales change by expected measurement error. Reliable improvement distinguishes such a change from a small numerical movement, while reliable recovery additionally considers caseness; neither removes the need to monitor deterioration and residual disability. Questionnaire accessibility, language and the validity of comparing groups require attention. Patients should understand why information is collected and how it contributes to care.

By May 2022, the clearest benefits were high outcome coverage, a transparent basis for improving implementation and a modest experimentally supported benefit from targeted feedback. Routine data had narrowed the gap between trial evidence and what services actually achieved. Further progress required responding intelligently to trajectories, preserving inclusive denominators and testing organisational changes, rather than treating measurement or a rising aggregate recovery figure as self-validating evidence of effectiveness.

Recent innovations offered plausible routes to better outcomes for delusions by replacing a broad, undifferentiated treatment target with specific maintaining processes. Persistent persecutory beliefs may be supported by worry, poor sleep, felt vulnerability, low confidence, reasoning inflexibility and safety behaviors. Changing one of these may create opportunities for a person to reconsider threat without demanding immediate agreement that their belief is wrong. The promise is mechanistic and practical; it does not imply that all delusions share one cause or that every plausible target will improve clinical outcomes.

A contributory-causal approach begins by identifying a potentially modifiable process, experimentally changing it and examining consequences for the clinical problem. Worry is an example: repeated anticipation of danger can generate threatening explanations and keep them mentally available. In the Worry Intervention Trial, Daniel Freeman and colleagues randomised 150 patients with persistent persecutory delusions to six sessions targeting worry alongside standard care, or standard care alone. Worry and delusion outcomes improved, with gains followed to 24 weeks. Because therapist contact was not matched, the result supports the added intervention package more securely than an exclusively worry-mediated effect.^[ref]

Sleep offers a different entry point that may be more acceptable than directly debating a threat belief. The OASIS trial randomised 3755 university students with insomnia to digital CBT for sleep or usual practice. It produced a large sleep benefit and smaller changes in paranoia and hallucinatory experiences. This supports testing sleep as a contributory process, while the nonclinical student sample and usual-practice comparator prevent direct inference that the same intervention treats persistent delusions in patients with psychosis.^[ref]

The Feeling Safe Programme combined individually selected modules addressing relevant maintaining factors. Its 2021 trial allocated 130 patients with persistent persecutory delusions to Feeling Safe or same-therapist befriending, with usual care continuing. The six-month adjusted difference in delusional conviction favoured Feeling Safe by about 10.7 points on a 0–100 scale. A categorical recovery comparison was less precise and did not reach conventional significance. The positive continuous primary outcome therefore should not be restated as a definitively superior recovery rate.^[ref]

Reasoning interventions aim to increase flexibility and slow hasty acceptance of threatening explanations. Philippa Garety and colleagues' SlowMo combined eight face-to-face sessions, digital material and a mobile application. In the 361-person analysis, the primary total paranoia score at 24 weeks did not show a statistically significant advantage over usual care, although several secondary and earlier outcomes favoured the intervention. There was no significant effect on jumping to conclusions. This mixed pattern is particularly important: an engaging, mechanistically informed treatment can show promising signals without meeting its prespecified primary test.^[ref]

These approaches could improve outcomes for several reasons. Targeting common difficulties such as insomnia or worry can give treatment an understandable starting point. Personalised modules can concentrate time on processes actually present instead of requiring every patient to complete the same sequence. Concrete experiments may provide more persuasive evidence than verbal reassurance. Digital support can make an exercise accessible between appointments, while carefully designed measures can show whether the nominated process changed before the belief or distress changed.

However, a target can be associated with delusions without causing them. Poor sleep and worry may partly reflect a common adversity, or lessen when general distress improves. An intervention intended for one process can alter several others, making a statistical mediator an uncertain guide to the active ingredient. Even when a factor contributes causally, changing it may produce only modest benefit because other maintaining processes remain. Necessary theoretical precision includes specifying who has the target, how much it must change and which outcome should follow.

Outcome choice can make an innovation appear more or less successful. Conviction, preoccupation, distress, activity, quality of life and diagnostic status are related but distinct. Greater doubt about a threatening explanation may be valuable without elimination of the belief; conversely, a questionnaire change need not restore work or social participation. The difference between SlowMo's primary and secondary findings illustrates why the endpoint and assessment time should be specified in advance. Multiple favourable secondary results cannot simply replace an unsuccessful primary test.

Clinical heterogeneity also matters. A treatment developed for persistent persecutory delusions is not automatically established for every delusional theme, acute state or diagnostic group. Language requirements, willingness to attend research therapy and referral patterns select who enters a trial. Comorbid depression, cognitive difficulties, substance use or continuing victimisation may alter the usefulness of a module. An unusual belief should be assessed in its cultural and social context; a psychological account must not assume that all reported threats are unreal.

Innovations can fail at implementation even when the trial mechanism is sound. Skilled research therapists, close supervision and protected time may be unavailable in routine services. A mobile application can increase opportunity for practice but also introduce access, privacy or comprehension barriers. Adding modules can increase burden, dilute effective content or delay the experiment that matters most. Patients may prefer a different target from the one selected by a questionnaire. Acceptability, fidelity, reach and cost therefore need direct measurement alongside symptom outcomes.

A strong next study would compare an adapted innovation with a credible active treatment in several services, with adequate power and blinded assessment. Prespecify primary conviction or distress outcomes, patient-prioritised functioning and longer-term maintenance. Measure candidate mechanisms repeatedly, recording which modules are actually received; module choice in a tailored treatment is not random and cannot itself identify the best component. A complementary factorial or sequentially randomised experiment could test specific additions while preserving adequate care for all participants.

By May 2022, the most convincing advance was the shift toward testable mechanisms and more rigorous, symptom-focused clinical comparisons. Worry, sleep, flexible reasoning and personalised threat-learning approaches offered reasons for optimism, with some positive clinical results and important null findings. Better outcomes would depend on genuine target engagement, adequate comparisons, generalisation and feasible delivery, rather than novelty, a digital format or a plausible causal diagram alone.